Japanese guidelines for the management of pemphigus

Masayuki Amagai, Akiko Tanikawa, Tomoko Shimizu, Takashi Hashimoto, Shigaku Ikeda, Michiko Kurosawa, Hironori Niizeki, Yumi Aoyama, Keiji Iwatsuki, Yasuo Kitajima

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The Committee for Guidelines for the Management of Pemphigus was organized as one element of the Japanese Dermatological Association (JDA) and the Ministry of Health, Labour, and Welfare (MHLW) Research Project on Measures for Research Committee for Intractable Skin Disease. Pemphigus has been defined as a group of intractable autoimmune blistering diseases caused by anti-desmoglein 1 and/or anti-desmoglein 3 IgG autoantibodies by the MHLW. The diagnosis of this condition and the criteria for assessing its severity are based on suggestions from the MHLW Research Group. The clinical practice guidelines presented here are those that are currently recommended in Japan. However, symptoms and complications can vary widely among individual pemphigus patients, so not all therapies will be required to be in complete agreement with these guidelines.

Original languageEnglish
Pages (from-to)471-486
Number of pages16
JournalJournal of Dermatology
Volume41
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Pemphigus
Guidelines
Health
Desmoglein 3
Desmoglein 1
Research
Practice Guidelines
Skin Diseases
Autoantibodies
Autoimmune Diseases
Japan
Immunoglobulin G
Therapeutics

Keywords

  • autoantibody
  • desmoglein
  • diagnosis
  • therapy

ASJC Scopus subject areas

  • Dermatology

Cite this

Amagai, M., Tanikawa, A., Shimizu, T., Hashimoto, T., Ikeda, S., Kurosawa, M., ... Kitajima, Y. (2014). Japanese guidelines for the management of pemphigus. Journal of Dermatology, 41(6), 471-486. https://doi.org/10.1111/1346-8138.12486

Japanese guidelines for the management of pemphigus. / Amagai, Masayuki; Tanikawa, Akiko; Shimizu, Tomoko; Hashimoto, Takashi; Ikeda, Shigaku; Kurosawa, Michiko; Niizeki, Hironori; Aoyama, Yumi; Iwatsuki, Keiji; Kitajima, Yasuo.

In: Journal of Dermatology, Vol. 41, No. 6, 2014, p. 471-486.

Research output: Contribution to journalArticle

Amagai, M, Tanikawa, A, Shimizu, T, Hashimoto, T, Ikeda, S, Kurosawa, M, Niizeki, H, Aoyama, Y, Iwatsuki, K & Kitajima, Y 2014, 'Japanese guidelines for the management of pemphigus', Journal of Dermatology, vol. 41, no. 6, pp. 471-486. https://doi.org/10.1111/1346-8138.12486
Amagai M, Tanikawa A, Shimizu T, Hashimoto T, Ikeda S, Kurosawa M et al. Japanese guidelines for the management of pemphigus. Journal of Dermatology. 2014;41(6):471-486. https://doi.org/10.1111/1346-8138.12486
Amagai, Masayuki ; Tanikawa, Akiko ; Shimizu, Tomoko ; Hashimoto, Takashi ; Ikeda, Shigaku ; Kurosawa, Michiko ; Niizeki, Hironori ; Aoyama, Yumi ; Iwatsuki, Keiji ; Kitajima, Yasuo. / Japanese guidelines for the management of pemphigus. In: Journal of Dermatology. 2014 ; Vol. 41, No. 6. pp. 471-486.
@article{6be21ccbbaf04a37965e7176553bb87b,
title = "Japanese guidelines for the management of pemphigus",
abstract = "The Committee for Guidelines for the Management of Pemphigus was organized as one element of the Japanese Dermatological Association (JDA) and the Ministry of Health, Labour, and Welfare (MHLW) Research Project on Measures for Research Committee for Intractable Skin Disease. Pemphigus has been defined as a group of intractable autoimmune blistering diseases caused by anti-desmoglein 1 and/or anti-desmoglein 3 IgG autoantibodies by the MHLW. The diagnosis of this condition and the criteria for assessing its severity are based on suggestions from the MHLW Research Group. The clinical practice guidelines presented here are those that are currently recommended in Japan. However, symptoms and complications can vary widely among individual pemphigus patients, so not all therapies will be required to be in complete agreement with these guidelines.",
keywords = "autoantibody, desmoglein, diagnosis, therapy",
author = "Masayuki Amagai and Akiko Tanikawa and Tomoko Shimizu and Takashi Hashimoto and Shigaku Ikeda and Michiko Kurosawa and Hironori Niizeki and Yumi Aoyama and Keiji Iwatsuki and Yasuo Kitajima",
year = "2014",
doi = "10.1111/1346-8138.12486",
language = "English",
volume = "41",
pages = "471--486",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Japanese guidelines for the management of pemphigus

AU - Amagai, Masayuki

AU - Tanikawa, Akiko

AU - Shimizu, Tomoko

AU - Hashimoto, Takashi

AU - Ikeda, Shigaku

AU - Kurosawa, Michiko

AU - Niizeki, Hironori

AU - Aoyama, Yumi

AU - Iwatsuki, Keiji

AU - Kitajima, Yasuo

PY - 2014

Y1 - 2014

N2 - The Committee for Guidelines for the Management of Pemphigus was organized as one element of the Japanese Dermatological Association (JDA) and the Ministry of Health, Labour, and Welfare (MHLW) Research Project on Measures for Research Committee for Intractable Skin Disease. Pemphigus has been defined as a group of intractable autoimmune blistering diseases caused by anti-desmoglein 1 and/or anti-desmoglein 3 IgG autoantibodies by the MHLW. The diagnosis of this condition and the criteria for assessing its severity are based on suggestions from the MHLW Research Group. The clinical practice guidelines presented here are those that are currently recommended in Japan. However, symptoms and complications can vary widely among individual pemphigus patients, so not all therapies will be required to be in complete agreement with these guidelines.

AB - The Committee for Guidelines for the Management of Pemphigus was organized as one element of the Japanese Dermatological Association (JDA) and the Ministry of Health, Labour, and Welfare (MHLW) Research Project on Measures for Research Committee for Intractable Skin Disease. Pemphigus has been defined as a group of intractable autoimmune blistering diseases caused by anti-desmoglein 1 and/or anti-desmoglein 3 IgG autoantibodies by the MHLW. The diagnosis of this condition and the criteria for assessing its severity are based on suggestions from the MHLW Research Group. The clinical practice guidelines presented here are those that are currently recommended in Japan. However, symptoms and complications can vary widely among individual pemphigus patients, so not all therapies will be required to be in complete agreement with these guidelines.

KW - autoantibody

KW - desmoglein

KW - diagnosis

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84902193647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902193647&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.12486

DO - 10.1111/1346-8138.12486

M3 - Article

C2 - 24909210

AN - SCOPUS:84902193647

VL - 41

SP - 471

EP - 486

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 6

ER -